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Dear Friends of WIPO Re:Search,
The World Intellectual Property Organization (WIPO) has a 
mandate to assist its 188 Member States to use intellectual 
property to meet society’s evolving needs.  We do so by, inter 
alia, creating public-private sector partnerships and capacity-
building programs to help developing countries gain access 
to valuable knowledge and facilitate technology transfer.  
WIPO Re:Search is a particularly successful example of our 
work in the field of global health.  The collaboration stories 
captured in this book are a sampling of our early progress 
and represent just the beginning of what we all expect to 
accomplish in the coming years.  
In 2015, WIPO Re:Search recorded a milestone of 100 
Members in total, including two new private sector 
companies, Takeda Pharmaceuticals of Japan and Johnson 
& Johnson of the United States of America.  The growth in 
membership and the commitment of the private sector are 
clear signals of the success WIPO Re:Search has seen to date.
I hope you will enjoy the collaboration stories and WIPO 
Re:Search statistics included in this book.
Sincerely,
 
Francis Gurry, Ph.D.
Director General, World Intellectual Property Organization 
Dear Colleagues,
Since its launch in October 2011, WIPO Re:Search has 
exceeded our greatest expectations.  We have made 
tremendous progress connecting researchers, facilitating 
collaborations, and advancing research and development 
in neglected tropical diseases, malaria, and tuberculosis. 
Members currently hail from 27 countries, with collaborations 
crossing oceans and spanning the globe. As of October 2015, 
BVGH has facilitated 95 agreements between WIPO Re:Search 
members.  Of the 95 agreements, 47 are ongoing and eight 
have met important development milestones.
This second biennial storybook highlights how far we have 
come, the impact we have had, the wide range of projects 
we are facilitating, and where we are headed. Twenty-five 
collaborations are featured in the storybook along with 
an overview of the Consortium’s accomplishments. These 
stories illuminate the variety and breadth of WIPO Re:Search 
collaborations established to date. 
I would like to express my sincere thanks to all WIPO Re:Search 
Members for their contributions to collaborations and their 
dedication to develop products to prevent, diagnose, and 
treat diseases of poverty. 
All of us at BVGH look forward to working with you in 2016.
Sincerely,
 
Jennifer Dent
President, BVGH
Message from the President, BVGHMessage from the Director General, WIPO
2 3
Francis Gurry, Ph.D. Jennifer Dent
WIPO Re:Search was founded by the World Intellectual Property Organization (WIPO) in partnership with BIO Ventures 
for Global Health (BVGH) and several leading pharmaceutical companies. The aim of the Consortium is to accelerate the 
development of new drugs, vaccines, and diagnostics for neglected tropical diseases (NTDs), malaria, and tuberculosis 
by connecting private industry assets and resources to qualified academic and non-profit researchers with product 
discovery or development ideas. Consortium membership includes academic and non-profit research institutions, 
governmental and non-governmental organizations, and biopharmaceutical companies. 
The WIPO Re:Search consortium is supported through the financial contributions of the pharmaceutical company 
Members – Alnylam Pharmaceuticals; Eisai Co., Ltd.; GlaxoSmithKline; Johnson & Johnson, Merck KGaA, Darmstadt, 
Germany; Merck & Co., Inc.; Novartis AG; Pfizer Inc.; Sanofi S.A.; and Takeda Pharmaceutical Company Ltd. These 
companies and other Provider Members contribute a wide variety of intellectual property (IP) assets including 
compounds and compound libraries, expertise and advice, reagents, and technologies. 
BIO Ventures for Global Health (BVGH)
BVGH was established in 2004 by the Biotechnology Industry Organization (BIO) to engage biopharmaceutical 
companies in global health initiatives. Today, BVGH continues to work closely with BIO and many other organizations to 
develop programs and create partnerships to improve health worldwide. As the Partnership Hub Administrator of WIPO 
Re:Search, BVGH plays a pivotal role in proactively identifying, establishing, and supporting collaborations. 
World Intellectual Property Organization (WIPO) 
WIPO is the United Nations agency dedicated to the use of IP to promote innovation for social, economic, and cultural 
development. WIPO manages a balanced and effective international IP system, in cooperation with its 186 member 
states and other relevant international organizations. As the Secretariat of WIPO Re:Search, WIPO plays a key role in 
overseeing the Consortium’s success. WIPO manages the online, publicly available WIPO Re:Search Database, which 
contains nearly 200 entries detailing Member contributions that range from compounds to diagnostic tools and more. 
Introduction to WIPO Re:Search
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WIPO Re:Search Overview
Collaboration Map
Pipeline of Ongoing Collaborations
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Partnered project  initiated
New Partner introduced
*Pipeline captures agreements put in
 place by October 15th, 2015
WIPO Re:Search at a Glance 2011-2015
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Collaboration Trends
Collaborations by Current Stage of Development
Collaborations
37 15 18 13 12
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Data/
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AssaySamples
Collaborations by Resources Shared
Collaborations by Sector*
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Basic research/
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8
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12
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t
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t
* In addition, there are four Industry + Industry collaborations.
Collaboration: Any sharing of IP assets, data, and expertise to advance research and development of NTDs, malaria, and 
tuberculosis
Industry: A pharmaceutical or biotechnology company
Non-profit: Academic institutions, research institutions, and product development partnerships
213
15 437
13 3511
7 211
16 246
Basic Research
31 7715
Total Collaborations
Malaria Tuberculosis Schistosomiasis Dengue
Drugs
Diagnostics
Industry  + Non-profit
Non-profit + Non-profit
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Portfolio of Select Diseases
98
*In addition, there are four Industry + Industry collaborations 
The following stories represent some of the many collaborations that have been catalyzed through WIPO 
Re:Search. This publication features collaborations that have been established since 2013.
Collaboration Stories
10
Glossary of Icons used in the Stories
Disease Causing Organism
Product
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Basic research/
Discovery
Hits ID Hit to Lead Preclinical
Development
Compounds Expertise/Advice Reagents Technology
targeting PAR1 could reduce mortality and, 
potentially, post-CM neurological complications. 
BVGH connected Dr. Craig to vascular biology 
experts at Eisai Co., Ltd. (Eisai) who have PAR1 
inhibitors to contribute to his research. Dr. 
Craig has obtained encouraging results after 
his first round of screening. BVGH is currently 
working with Dr. Craig and the scientists at Eisai 
to explore different approaches to move this 
project forward.  
“WIPO Re:Search provides a proactive approach to identifying 
potential research groups that could benefit from input 
from industrial partners. This is particularly important for 
diseases that principally affect areas of the world with limited 
resources by providing a platform for researchers often 
working within academia to gain added value from the 
investment in people and research delivered by industry.” 
- Dr. Alister Craig, LSTM
C erebral malaria (CM) is the most severe neurological complication of the infection 
by the parasite Plasmodium falciparum, resulting 
in seizures, coma, and death. With over 500,000 
cases annually, children in sub-Saharan Africa 
are the most affected. Mortality is high, and 
around 25% of survivors develop neurological 
complications and cognitive impairment.
The pathology of CM is not fully understood 
but is thought to involve interactions between 
P. falciparum-infected erythrocytes (IE) and host 
endothelial cells. In a recent study in Malawi, 
brain swelling was found to be strongly linked 
with fatal outcomes in CM. The cause of this 
swelling is probably multi-factorial, involving 
inflammation, cell death, and IE accumulation. 
Recent work from Dr. Alister Craig, Dr. Chris 
Moxon, and colleagues at the Liverpool School 
of Tropical Medicine (LSTM) and University 
of Liverpool identified a role for protease-
activated receptor (PAR) 1 in this pathway. Their 
research has shown that during P. falciparum 
cerebral infection, PAR1 may be activated by 
an alternate pathway. This altered activation 
causes the PAR1 pathway to initiate a pro-
inflammatory response, causing coagulation 
and inflammation.
Dr. Craig’s group has developed a live 
endothelium model co-cultured with IE to study 
these interactions in vivo. Given the critical role 
of PAR1 in the altered signaling process, Dr. 
Craig wanted to test a range of PAR1 inhibitors 
using this model. His hypothesis is that this 
PAR1-mediated coagulation/inflammation 
pathway plays a significant role in endothelial 
barrier loss in CM, and that adjunct treatments 
Eisai Co., Ltd.
Liverpool School of Tropical Medicine
“WIPO Re:Search provides the pharmaceutical industry a very unique and exciting opportunity 
to contribute to research in the field of NTDs. It provides a platform for our compounds, 
originally developed for lifestyle diseases, to be born again either as drug candidates or 
conduits for proof-of-concept development for neglected disease therapeutics. We hope more 
companies and funders join the Consortium and drive this valuable pre-competitive 
opportunity to accelerate NTD R&D.”  - Dr. Makato Asada, Eisai
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“WIPO Re:Search has been very important in facilitating collaborations and furthering the various 
research agendas for NTDs. This is greatly appreciated.” - Dr. Conor Caffrey, UCSD 
Dr. Conor Caffrey is an Associate Professor at the Skaggs 
School of Pharmacy and Pharmaceutical Sciences at the 
University of California, San Diego. He and his team are 
particularily focused on basic and applied biology of tropical 
parasitic diseases including schistosomiasis, hookworm 
diseases, and African trypanosomiasis.
Note:
The team of GSK scientists that developed PKIS1 and PKIS2 
recently moved to the University of North Carolina (UNC), 
Chapel Hill (https://pharmacy.unc.edu/research/sgc-unc/ ). 
In order to further support the growing list of collaborations 
based on kinase inhibitor sharing, GSK licensed PKIS1 and 
PKIS2 to UNC Chapel Hill. Interested parties can reach out 
to the UNC team with questions about the kinase inhibitor 
sharing initiative by sending an e-mail to sgc-unc@unc.edu. 
K inases are involved in key cellular processes and are chemically tractable drug targets. However, 
less than 5% of the human kinome has been 
explored with selective small molecule inhibitors. 
To demonstrate the enzymes’ therapeutic utilities, 
GlaxoSmithKline (GSK) has compiled two sets of 
kinase inhibitors, Published Kinase Inhibitor Set 1 
(PKIS1) and Set 2 (PKIS2), and is sharing these sets 
with academic researchers to advance biological 
evaluation and pharmacological understanding of 
the unmapped human kinome. 
Given the usefulness and versatility of these 
inhibitors, GSK is currently collaborating with 
over 100 researchers to explore the full use of the 
compounds. A few notable diseases being studied 
through WIPO Re:Search include tuberculosis, 
malaria, and schistosomiasis. Described below is one 
such collaboration.
Polo-like kinases (Plks) are important regulators of cell 
cycle progression and mitosis. In mammals there are 
five Plks (Plk 1-5). SmPlk1 and SmSak—homologous 
to Plk1 and Plk4 respectively—are expressed in the 
parasitic worm Schistosoma mansoni. Dr. Conor 
Caffrey of the Center for Discovery and Innovation 
in Parasitic Diseases (http://www.cdipd.org/) at 
the University of California, San Diego (UCSD) has 
evidence from whole-organism screens that specific 
inhibition of SmPlk1 by commercially available 
inhibitors of human Plk1 kills the helminth. To further 
the investigation of SmPlk1 as a potential target 
for disease intervention, BVGH connected UCSD 
and GSK. GSK agreed to provide Dr. Caffrey with 
PKIS1 and PKIS2. The sets, which contain 367 and 
539 compounds respectively, include specific Plk 
inhibitors. The results of Dr. Caffrey’s screens will be 
released soon.
GlaxoSmithKline
University of California, San Diego
Dr. Santiago Ramon-Garcia, UBC
“WIPO Re:Search was instrumental in bringing together the expertise needed to move this project 
forward. They definitely catalyzed this productive collaboration.” - Dr. Charles Thompson, UBC
B uruli ulcer is a chronic, debilitating infectious disease that primarily affects 
children in impoverished communities. Over 
40,000 cases have been reported worldwide 
in the last decade, primarily in tropical and 
sub-tropical regions. If not detected and treated 
early on, 25% of infections lead to permanent 
disability. 
Buruli ulcer is caused by Mycobacterium 
ulcerans, a bacterium closely related 
to the causative agents of tuberculosis 
(Mycobacterium tuberculosis) and leprosy 
(Mycobacterium leprae).  Although Buruli ulcer 
can be effectively treated, current therapeutic 
options are limited, lengthy, and unpleasant.  
The first line anti-tuberculosis drug rifampicin 
is typically co-administered for eight weeks 
with the injectable drug streptomycin (which 
has severe side-effects including ototoxicity). 
Given the propensity of bacteria to develop 
resistance, the development of an alternate 
treatment regimen is of critical importance.
To accelerate drug discovery, Dr. Gerd 
Pluschke, a researcher at the Swiss Tropical 
and Public Health Institute (Swiss TPH) in 
Basel, Switzerland, is interested in repurposing 
potent tuberculosis drugs for treating Buruli 
ulcer.  Dr. Charles Thompson and Dr. Santiago 
Ramon-Garcia from the University of British 
Columbia (UBC) in Canada have discovered that 
certain avermectins, a family of compounds 
with anthelmintic activities used to treat river 
blindness in people and roundworms in pets, 
were active as antibiotics against M. tuberculosis. 
BVGH connected Dr. Pluschke with Drs. 
Thompson and Ramon-Garcia to discuss the 
possibility of assessing these avermectins 
against M. ulcerans. Dr. Pluschke and his 
Associate Researcher, Dr. Nicole Scherr, 
assessed the set of avermectins provided by 
UBC against the bacterium. The data from 
these assays, together with an appraisal of 
published pharmacokinetic properties of the 
avermectins, demonstrated that selamectin 
was most promising for clinical application 
(recently published in PLOS Neglected Tropical 
Diseases 9: e0003996 doi: 10.1371/journal.
pntd.0003996, 2015). 
The results of this collaboration have paved 
the way for the development of a new, 
alternative treatment option for Buruli ulcer. 
Given these exciting results, new partners 
who will bring in the expertise and the 
infrastructure needed to move this project 
forward are being sought. 
University of British Columbia
Swiss Tropical and Public Health Institute
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Dr. Tanweer Khan, Merck & Co., Inc.
“BVGH was the conduit that allowed for facile discussions that moved quickly to agreement 
negotiations and signature. Working with Alan’s team of expert scientists is exactly the kind of 
partnership we look for whereby we can employ an important company asset and our drug-hunting 
expertise in collaboration with world expert scientists to address a disease area of incredible medical 
need. Doing science like this is not work – it is fun and incredibly rewarding for all involved.” 
- Dr. David Olsen, MSD 
This work forms part of Merck’s long-standing 
commitment to discovering, developing, and 
delivering novel medicines in the global fight against 
infectious disease through both in-house research 
and engagement with external partners (http://www.
merckresponsibility.com/access-to-health/infectious-
diseases/).
By screening Merck’s set of small molecule aspartyl 
protease inhibitors using WEHI’s high-throughput 
assay, the team expects to identify chemically 
tractable hits that target PMV. The initial results of the 
screen seem promising, and Merck will continue to 
share medicinal chemistry expertise to help advance 
initial hits. Recognizing the need to find additional 
financial support for this progressing collaboration, 
BVGH suggested that Merck and WEHI jointly apply 
for a Wellcome Trust funding opportunity aimed at 
stimulating partnerships between non-profit and 
for-profit entities. The parties successfully obtained 
funding, and the team hopes to advance the 
development of a new, broad-spectrum anti-malarial 
drug into development.
S ince the early 2000s, the estimated global mortality rates due to malaria have decreased by 47%. 
Emerging parasite resistance to current therapies 
threatens this progress and resistance to anti-malarial 
drugs has been documented in three of the five malaria 
species known to affect humans. 
Researchers are actively looking for new anti-malarial 
drugs that are less likely to result in resistance. One 
approach involves targeting plasmepsin V (PMV), 
a Plasmodium enzyme that is encoded by a highly 
conserved gene and therefore may offer a target with 
a high barrier to resistance. PMV regulates the export of 
Plasmodium proteins that remodel the host’s infected 
red blood cells (RBC). This RBC remodeling is essential 
for the parasite’s survival, enabling it to acquire nutrients 
and evade the host immune response. 
Dr. Alan Cowman, a Howard Hughes Medical Institute 
investigator at the Walter and Eliza Hall Institute of 
Medical Research (WEHI) in Australia, and his colleagues, 
Dr. Justin Boddey and Dr. Brad Sleebs, are studying the 
function of proteins involved in parasite invasion and 
host cell remodeling. They have developed a high-
throughput assay to screen for compounds that can 
inhibit PMV in both P. falciparum and P. vivax, the two 
parasites responsible for the vast majority of malaria 
cases. The Cowman/Boddey/Sleebs laboratories are 
interested in identifying aspartyl protease inhibitors 
that are likely to target PMV, an aspartic acid proteolytic 
enzyme. At the US-based pharmaceutical company, 
Merck & Co., Inc. (known as MSD outside the United 
States and Canada), Dr. Tanweer Khan recognized that 
the company had many drug-like aspartyl protease 
inhibitors in its chemical libraries that could potentially 
impact the replication of malaria. Merck approached 
BVGH with an interest in possibly repurposing these 
inhibitors, previously made for other therapeutic targets, 
as agents against malaria. BVGH connected the two 
organizations. 
Merck & Co., Inc. 
Walter and Eliza Hall Institute of Medical Research
Dr. Jim McKerrow, UCSD
“WIPO Re:Search continues to play a key role for us in brokering collaborations with biotech and 
pharma. Because we are working on neglected tropical diseases, having WIPO/BVGH on the lookout 
for new drug candidates or technology is an invaluable resource.” - Dr. Jim McKerrow, UCSD 
absent in mammalian cells, making the parasite 
enzymes responsible for catalyzing ergosterol 
synthesis ideal drug targets. CYP51 and squalene 
synthase—enzymes involved in the multistep 
catalysis of ergosterol—have been demonstrated to 
be promising drug targets in T. cruzi and Leishmania. 
Targeting multiple enzymes within a single 
metabolic pathway is an accepted method of 
limiting the development of drug resistance. Having 
previously demonstrated that CYP51 inhibitors are 
effective against T. cruzi and Leishmania, Drs. Larissa 
Podust, Jim McKerrow, and Jair Siqueira-Neto from 
the University of California, San Diego (UCSD) were 
interested in identifying inhibitors of an additional 
enzyme in the parasites’ ergosterol synthesis 
pathways. 
Eisai Co., Ltd. (Eisai), a founding member of the 
WIPO Re:Search consortium, contributed E5700, 
a novel squalene synthase inhibitor originally 
developed to treat atherosclerosis, to the WIPO 
Re:Search Database. Based on previous studies 
by Dr. Julio Urbina and colleagues establishing 
E5700’s important role in targeting the catalysis of 
ergosterol, Dr. McKerrow hypothesized it would 
be an ideal drug candidate to co-administer 
with a novel CYP51 inhibitor. BVGH conveyed Dr. 
McKerrow’s interest and request to Eisai, and they 
agreed to share E5700 with the UCSD researchers. 
Drs. Podust, McKerrow, and Siqueira-Neto will 
assess E5700 alone and in combination with a novel 
CYP51 inhibitor for efficacy against both T. cruzi 
and Leishmania. If synergistic effects are observed, 
these compounds could be further optimized into 
a potentially more efficient and effective treatment 
for Chagas disease and leishmaniasis.
C hagas disease and leishmaniasis, two parasitic diseases caused by pathogens belonging to 
the Trypanosomatidae family, collectively infect 
nearly 22 million people worldwide and result in 
approximately 60,000 deaths annually. Current 
treatments for both are often long, expensive, 
and limited by significant side effects. Despite the 
availability of treatment options, chronic Chagas 
disease and visceral leishmaniasis—the most 
advanced forms of the diseases—are not curable. 
The sterol biosynthesis pathway is an attractive 
target to develop new treatments as sterols are 
critical in maintaining proper stability of eukaryotic 
cell membranes. Specifically, Trypanosoma cruzi 
(T. cruzi, the causative agent of Chagas disease) 
and Leishmania require membrane ergosterols for 
growth and viability. Interestingly, ergosterols are 
Eisai Co., Ltd.
University of California, San Diego
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“This platform demonstrates how intellectual property can be activated to be a promoter of 
access rather than a barrier. WIPO Re:Search will provide the opportunity for Merck to share 
its vast compound library with experts in the global research community focused on 
developing novel compounds to combat infectious diseases.” - Dr. Arno Hartmann, Head of 
Patents Pharmaceuticals, Merck KGaA, Darmstadt, Germany
“Joining WIPO Re:Search is an example of how Merck is 
going the extra mile in addressing access and intellectual 
property barriers by encouraging collaboration between 
partners in the North and South to accelerate early 
discovery for infectious diseases.” - Dr. Frédérique Santerre, 
Global Head, Access to Health, Merck KGaA, Darmstadt, 
Germany
Onchocerciasis: One Disease, Two 
Approaches
O nchocerciasis, commonly known as river blindness, is a debilitating neglected tropical 
disease that affects approximately 26 million people 
across the world, causing visual impairment in up 
to 1-2 million people, of which 270,000 people are 
rendered completely blind. This disease, which is 
predominant in sub-Saharan Africa, is caused by the 
parasitic worm Onchocerca volvulus and is spread via 
the bite of black flies of genus Simulium damnosum.
Despite being the second leading infectious cause 
of blindness globally, there is no available treatment 
that can cure or resolve the infection. Ivermectin 
is currently the only recommended drug.  It kills 
the juvenile worms (microfilariae) but is ineffective 
against the microfilariae-producing adult worms. To 
completely clear the parasite, infected individuals 
must take ivermectin annually over the entire life 
span of the adult worm—up to 14 years.  Mass drug 
administration (MDA) of ivermectin has eliminated 
or significantly reduced the burden of the disease in 
many endemic villages. Unfortunately, concomitant 
killing of the microfilariae of the African eye worm 
Loa loa by ivermectin can cause severe adverse 
events in humans, including encephalopathy and 
death. Therefore, ivermectin MDA was halted in 
co-endemic communities, most notably in West 
and Central Africa, making it such that a new drug is 
desperately needed for these regions.
Dr. Fidelis Cho-Ngwa, of the Biotechnology Unit at 
the University of Buea in Cameroon, has developed 
a highly efficient, medium-throughput, whole-
parasite system to screen small molecules and 
natural product extracts to identify compounds 
that selectively kill both microfilariae and adult O. 
volvulus, without also killing Loa loa microfilariae. 
Below is the description of two collaborations 
that BVGH has facilitated towards one common 
goal: to generate high quality drug leads that will 
support global pipelines for the development of 
an onchocerciasis cure that can be used in Loa loa 
endemic regions.
Collaboration with Merck KGaA, 
Darmstadt, Germany
Heat shock protein 90 (Hsp90) is a molecular 
chaperone involved in the trafficking of proteins 
in the cell. It is one of the most highly expressed
Merck KGaA, Darmstadt, Germany
University of Buea
“WIPO Re:Search is a game changer in the field of neglected 
tropical diseases. It is breaking barriers that hitherto seemed 
impossible to break. Within only two years of working with 
WIPO Re:Search, we (at the University of Buea) have been 
able to achieve what some of our predecessors who worked 
without the platform could not achieve in a decade.” 
- Dr. Fidelis Cho-Ngwa
cellular proteins across all species and is essential 
in all eukaryotes. Previous work has shown that 
Hsp90 inhibitors are potent against Brugia pahangi 
microfilariae and adults. B. pahangi is a microfilarial 
nematode similar to O. volvulus. Thus, the Hsp90 of 
Onchocerca is expected to be a similarly efficacious 
drug target. Merck KGaA, Darmstadt, Germany has 
2.5 million diverse small molecules in its portfolio, 
including Hsp90 inhibitors. Merck KGaA, Darmstadt, 
Germany will provide Dr. Cho-Ngwa with a subset 
of these highly potent molecules, mostly Hsp90 
inhibitors, to screen against Onchocerca. Dr. Cho-
Ngwa will follow the initial screening to counter-
select against Loa loa. This will involve both in vitro 
and in vivo screens. The best leads will be advanced 
in subsequent steps by the concerted efforts 
of both Merck KGaA, Darmstadt, Germany, the 
University of Buea, and other partners, if required.
BVGH’s FundFinder program was used to secure 
funding for this important initiative. BVGH identified 
the Wellcome Trust PathFinder award—a funding 
opportunity aimed at stimulating partnerships 
between pharmaceutical companies and academic 
research institutes. Dr. Cho-Ngwa jointly applied 
with Merck KGaA, Darmstadt, Germany and was 
successful in securing funding from the Wellcome 
Trust. 
Collaboration with University of 
British Columbia (UBC)
In addition to screening synthetic small molecules, 
Dr. Cho-Ngwa explores the potential of natural 
products against Onchocerca. Using his medium-
throughput assay, he identified several natural 
products with activity against both microfilariae and 
adult Onchocerca. In order to move his screening 
hits forward, BVGH connected Dr. Cho-Ngwa with 
University of British Columbia
University of Buea
“I am delighted that BVGH introduced me to Professor Cho-Ngwa from the University of Buea. 
Professor Cho-Ngwa has developed an innovative screen for small molecules that have the 
potential to be developed into new drugs to treat river blindness, and he has identified crude 
extracts of several African plants that show promising activity. We are excited to be helping his 
research by identifying the chemical structures of the active natural products in his active 
crude extracts.” - Dr. Raymond Andersen, UBC
Dr. Raymond Andersen, an organic chemist at 
UBC. Dr. Andersen has the essential technologies, 
expertise, and experience needed to fractionate and 
identify active compounds from natural product 
extracts. Dr. Andersen will perform activity-guided 
fractionation, in collaboration with Dr. Cho-Ngwa, 
to isolate and subsequently characterize the 
extracts’ active compounds, including structure 
determination. With this knowledge in hand, both 
Dr. Cho-Ngwa and Dr. Andersen will be better 
positioned to develop these compounds into a new 
treatment for onchocerciasis.
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“WIPO Re:Search  plays a key role in connecting 
academic and industry partners working on areas where 
industry otherwise would not be working. Another 
important contribution of WIPO Re:Search is in 
facilitating connections between diverse researchers with 
complementary expertise towards a larger goal. I am very 
positive about this collaboration and expect it to unlock 
some very important targets for malaria eradication.” 
- Dr. Agam P. Singh, NII
“This collaboration between Alnylam, the National Institute of Immunology, and Northeastern 
University could lead to more effective and safer therapies for malaria.” 
– Dr. Mansoor Amiji, NEU
W ith half of the world’s population living in areas at risk for transmission, malaria is one of the most 
severe public health concerns worldwide.  The disease 
has two stages in the human host—an obligatory 
asymptomatic liver-stage followed by a symptomatic 
blood stage. Treating malaria symptoms requires 
clearing blood-stage parasites, and appropriately, 
most antimalarial drug discovery efforts have largely 
focused on developing therapeutics against blood-
stage parasites. However, inhibiting the liver stage, 
when the lower parasite burden might delay resistance 
development, presents a more attractive approach 
for prophylaxis. Yet presently there are no approved 
liver-stage therapies with the exception of primaquine, 
which is contraindicated during pregnancy and in 
people with glucose-6-phosphate dehydrogenase 
(G6PD) deficiency, a widespread phenotype across 
malaria endemic regions.
Accordingly, Dr. Agam P. Singh at the National Institute 
of Immunology (NII) in Delhi, India is working to identify 
a drug target for liver-stage malaria. He has found four 
host-based transcription factors that he believes affect 
the severity of liver-stage malaria infection. In order to 
analyze their role, he is interested in knocking down 
these genes in the in vitro and in vivo models that he 
has developed. One approach to knocking down 
genes is through RNA interference (RNAi). Given their 
expertise in this field, BVGH connected Dr. Singh with 
the scientists at Alnylam Pharmaceuticals in Cambridge, 
Massachusetts. Currently Dr. Greg Hinkle and his group 
at Alnylam have completed designing and synthesizing 
optimized small interfering RNAs (siRNAs) against 
these Plasmodium genes. Another challenge in getting 
efficient gene knockdown is the delivery and targeting 
of the siRNAs within the tissue. To complete this puzzle, 
BVGH introduced a third collaborator, Dr. Mansoor 
Amiji at Northeastern University (NEU) in Boston, 
Massachusetts. Dr. Amiji, an expert in target-specific 
delivery systems, will encapsulate the siRNAs in 
nanoparticles that target the hepatocytes (liver 
cells). Once Dr. Singh is able to confirm that the 
siRNAs are successful in knocking down the genes 
in his in vitro cell line, the encapsulated siRNAs 
will then be tested for efficient knockdown of the 
host genes in his in vivo mouse model. His hope 
is to eventually study the effect of these gene 
knockdowns in the parasite challenge model.
Ultimately this analysis will help the team identify 
host proteins that could then be targeted for novel 
drug development for liver stage-malaria thus 
addressing a significant therapeutic void.
Alnylam Pharmaceuticals/Northeastern University
National Institute of Immunology
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“I am very grateful to BVGH for establishing our collaboration. Undergraduate students received a 
‘real world’ experience as well as an opportunity to learn from Regina.  Working in partnership has 
made teaching undergraduate research more fun and meaningful – we also achieved great results. 
We plan to write a publication and grant proposal after the fall quarter!” 
– Dr. Sue Kraemer, UW Bothell
“The collaboration between NMIMR and UW Bothell fostered 
by our partner, BVGH/WIPO Re:Search, has been a great 
experience so far. The commitment and enthusiasm of 
each contributor, including students, toward this important 
biomedical research is remarkable. I am confident that the 
effort will culminate in more effective therapies not only for 
Ghanaians or Africans, but also various populations.” 
– Dr. Regina Appiah-Opong, NMIMR
M etabolism of most drugs—such as those developed to treat HIV/AIDS, malaria, and 
tuberculosis—is mediated by members of the 
cytochrome P450 superfamily of monooxygenases 
(CYPs), most notably CYP3A4 and CYP2D6.  
Differences in drug response are influenced by these 
enzymes’ abilities to metabolize a drug, which in turn 
can be altered by single nucleotide polymorphisms 
(SNPs) in the CYP genes. Certain ethnic groups 
have unique SNPs that correlate with altered drug 
responses. As such, a comprehensive understanding 
of SNPs in the CYP genes within all populations is 
essential to ensure drugs are safe and efficacious for 
all. 
Dr. Regina Appiah-Opong from the Noguchi Memorial 
Institute for Medical Research (NMIMR) in Ghana 
studies the potential of CYP-mediated drug-drug and 
herb-drug interactions of drugs and plant medicines 
used to treat malaria, tuberculosis, and HIV/AIDS 
(among others) in the Ghanaian population.  In order 
to assess accurately the drug interaction potentials 
of these medicines, Dr. Appiah-Opong is focusing 
her research on CYP genes to identify the differences 
in SNPs between Caucasian and African ethnicities, 
particularly SNPs specific to Ghanaian people. To 
support her endeavors, BVGH connected Dr. Appiah-
Opong with Dr. Susan Kraemer, a bioinformatics 
instructor at the University of Washington Bothell (UW 
Bothell).
The two researchers agreed to provide Dr. Kraemer’s 
undergraduate students with real-life bioinformatics 
experience; the students were instructed to analyze 
publicly available CYP gene sequences. These 
sequences include the recent data generated by the 
1000 Genomes Project. Based on their analyses, the 
students identified genetic differences in CYP genes 
between African and Caucasian populations. Students 
in the first offering of the course found striking 
differences between particular alleles for CYP3A4 and 
CYP2D6 in the two populations. Due to the encouraging 
results and availability of human genome sequence data 
from a recently published African Genome variation 
project, Drs. Kraemer and Appiah-Opong were granted 
access to the Ghanaian DNA sequence information from 
the African Partnership for Chronic Disease Research 
(APCDR). Using these data, in addition to the data from 
the 1000 Genomes Project, Dr. Kraemer will lead another 
undergraduate class investigating the population-specific 
alleles. These analyses will improve our understanding 
of population variation of the CYP enzymes and will 
allow Dr. Appiah-Opong to clone Ghanaian-specific 
CYP vectors and conduct drug metabolism studies. 
Significant differences in drug metabolism between 
these enzymes and control CYPs would highlight 
the need for expanded clinical trials among different 
ethnicities. The results of this collaboration may lay the 
groundwork for changing approaches to drug approval 
in Ghana and in other regions of the world.
University of Washington Bothell
Noguchi Memorial Institute for Medical Research
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“The connections made by BVGH and the opportunities that have been presented 
to my students and me through WIPO Re:Search have been invaluable,” stated Dr. 
Wellington Oyibo, Director, Research and Innovation, University of Lagos, 
Nigeria.  “My laboratory and students have beneted through the many research 
partnerships and scientic exchanges facilitated. The impact of these experiences 
will be long-lasting for each of us and for the University.” 
University of Lagos faculty to Novartis: 
BVGH coordinated a research placement for 
Dr. Oyibo at Novartis’ headquarters in Basel, 
Switzerland. Dr. Oyibo gained experience in 
product development processes, as well as 
insights into clinical trial management. 
Funding for this program was secured by 
WIPO from the Australian government.
With the shift in focus from malaria control to malaria 
elimination, Dr. Oyibo is interested in developing 
diagnostics that can detect asymptomatic malaria. After 
receiving samples from Nigerian patients with severe or 
asymptomatic malaria and from healthy individuals, Dr. 
Bach will use a proteomic approach to identify dierently 
expressed biomarkers in the three population types that 
could be incorporated into a suitable platform for malaria 
diagnosis. 
Dr. Jun-Hu Chen, Vice Chief and Associate Professor at 
NIPD, has developed PCR assays to identify resistance-
causing mutations in malaria parasite genes. With funding 
from NIPD, Uche Igbasi from the University of Lagos spent 
two months at NIPD to receive training on the PCR assay 
while using samples from Nigerian patients to look for 
mutations causing resistance to drugs. This collaboration 
will provide a tool to monitor region and time-specic 
trends in antimalarial resistance in Lagos, Nigeria.
University of Lagos PhD 
student to NIPD/China: BVGH 
facilitated the placement of a 
graduate student from Dr. Oyibo’s 
laboratory, Uche Igbasi, in Dr. 
Jun-Hu Chen’s laboratory at NIPD 
(see inset below).
Dr. Oyibo attended an IP 
training workshop hosted by 
WIPO in Geneva, Switzerland.
McGill University + University of Lagos: To 
address the need to develop malaria 
diagnostics that have high sensitivity and 
rapid turnaround, Dr. Oyibo and Dr. Paul 
Wiseman (McGill) are working together to 
develop a eld-based malaria diagnostic 
utilizing the biomarker, hemozoin (see story 
on page 30).
University of British Columbia 
(UBC) + University of Lagos: BVGH 
facilitated two collaborations 
between Dr. Oyibo and Dr. Horacio 
Bach (UBC). One collaboration led to 
a master’s thesis project for Dr. 
Oyibo’s student to explore the role of 
ICAM1 inhibition for decreasing 
malaria severity. The second 
collaboration involved looking for 
biomarkers in malaria-infected 
people using mass spectrometry (see 
inset below).
Stanford faculty to University of Lagos:
BVGH placed Dr. Manu Prakash (Stanford) at 
the University of Lagos to conduct eld 
studies and test the feasibility of a point-of-
care microscopy diagnostic tool (Foldscope) 
that he developed for malaria. During his visit, 
Dr. Prakash conducted training workshops on 
the Foldscope and received user input.
University of Lagos PhD student 
to Stanford: BVGH facilitated the 
placement of a graduate student 
from Dr. Oyibo’s laboratory, Chika 
Okangoba, in Dr. Ben Pinsky’s 
laboratory (Stanford) to advance 
student education and training 
(see story on page 28).
Uche Igbasi, 
University of Lagos
Legend
Activity
Collaboration
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“WIPO Re:Search is doing outstanding work by mediating collaborations of researchers in order to 
advance the understanding, diagnosis, and therapeutics of neglected diseases. In addition, BVGH 
follows up on collaborations, which allows us to track the development of our projects in a timely 
fashion. We strongly believe we can provide  the basic tools required  to accelerate the development 
of novel therapies and diagnostics in order to curb the expansion of neglected diseases.” - Dr. Horacio 
Bach, UBC
“P. vivax has been shown to cause severe illness and 
death, and upwards of 80 million clinical infections per 
year have been estimated. We hope that our 
collaboration with Dr. Bach will lead to novel findings 
that will help define a repertoire of inhibitory antibodies 
that are effective in blocking the entry of P. vivax into 
RBCs.” –Dr. Wai-Hong Tham, WEHI
I t is increasingly clear that a greater understanding of host-pathogen interactions—
such as those between a human and malaria 
parasite—is essential to the development of new 
treatments and, most importantly, a vaccine for 
malaria. Entry into a host’s red blood cells (RBCs) 
is a key step in the complex life cycle of the 
malaria parasite that triggers downstream events 
leading to the development of the symptomatic 
phase of the infection. Malaria parasites have 
evolved to express several different molecules 
that induce entry following interaction with 
RBC surface receptors. Much is known about 
the interaction between RBCs and Plasmodium 
falciparum—the malaria parasite that causes 
the most severe form of malaria. However, the 
interaction between Plasmodium vivax (P. vivax), 
the parasite responsible for the most frequent 
and widely distributed form of recurring malaria, 
and host RBCs is less well understood. 
Dr. Wai-Hong Tham, a malaria researcher at 
the Walter and Eliza Hall Institute of Medical 
Research (WEHI) in Melbourne, Australia, studies 
how malaria parasites enter RBCs and evade the 
host immune response. Dr. Tham is specifically 
interested in identifying high-affinity antibodies 
that block P. vivax proteins from binding to the 
surface of RBCs, thereby blocking entry. BVGH 
suggested a collaboration between Dr. Tham 
and Dr. Horacio Bach, who heads the antibody 
engineering facility at the University of British 
Columbia (UBC) in Vancouver, Canada. Using 
phage display, Dr. Bach is identifying human-
derived, high-affinity recombinant antibodies 
against a specific P. vivax protein for Dr. Tham. 
Following Dr. Bach’s selection of high-affinity 
antibodies, Dr. Tham will determine which of 
these antibodies block P. vivax entry into RBCs. 
Dr. Tham will subsequently use the antibodies 
to map the protein epitopes that are required 
for RBC binding. Entry into RBCs results in the 
symptoms of malaria and is also essential for the 
parasite’s differentiation into its transmissible 
form. By understanding how P. vivax enters RBCs, 
Dr. Tham and other scientists will be better 
equipped to develop therapeutics or vaccines 
that mitigate symptoms and/or prevent P. vivax 
transmission.
University of British Columbia
Walter and Eliza Hall Institute of Medical Research
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Photo Credit: Czesia Markiewicz, WEHI
Prof. Karl Hoffmann and Dr. Kathy Geyer, 
Aberystwyth University
I nfection with cercariae of the trematode genus Schistosoma (commonly known as blood flukes) 
leads to the devastating illness schistosomiasis. This 
neglected infectious disease afflicts more than 240 
million people worldwide (mostly children), often in 
resource-deprived tropical and sub-tropical regions 
where exposure to contaminated water containing 
cercariae is unavoidable. The main anthelmintic 
used to treat schistosomiasis, praziquantel, is only 
effective in treating the adult worm. This limited 
efficacy, along with the potential of resistance 
development due to mass drug administration 
programs, highlights an urgent need for new 
therapies.
Responding to this need, researchers at 
Aberystwyth University in Wales, led by Prof. Karl 
Hoffmann, are developing new approaches for 
controlling parasitic helminths. Prof. Hoffmann’s 
group has partnered with Alnylam Pharmaceuticals 
(Alnylam) to explore the use of ribonucleic acid 
interference (RNAi) technology for gene silencing in 
S. mansoni (one of the three main trematode species 
that cause the disease in humans) to identify targets 
that are important for the survival of this medically 
important parasite.
Dr. Brian Bettencourt, a biometrics researcher 
at Alnylam, optimized a set of short interfering 
RNAs (siRNAs) for Prof. Hoffmann to assess in gene 
knockdown studies in S. mansoni. The optimized 
siRNAs designed by Alnylam were demonstrated 
to be more effective than previously tested siRNAs. 
Given these promising results, Alnylam supported 
the design of additional siRNAs against three S. 
mansoni genes. To optimize the knock-down, 
Alnylam is also providing lipophilic reagents and 
advice on the delivery of the siRNAs in S. mansoni. 
With this additional support from Alnylam, Prof. 
Hoffmann’s team plans to demonstrate proof-of-
principle and establish an optimized protocol for 
gene silencing in schistosomes. Ultimately, the 
group envisages applying for funding to conduct 
a genome-wide screen in S. mansoni using siRNAs 
designed with Alnylam’s technology, with the aim 
of identifying gene targets for developing next-
generation anthelmintics.
“Alnylam has a rich history of collaborating with academic and other research institutions to explore 
the use of RNA interference in identifying gene targets for the development of innovative medicines,” 
said Rachel Meyers, Senior Vice President of Research at Alnylam. “We are happy to be working with 
the team at Aberystwyth University and providing materials that could enable the further 
development of a medicine for this neglected tropical disease.”
Alnylam Pharmaceuticals
Aberystwyth University
Dr. Rachel Meyers, Senior VP, Alnylam
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“Project scouting activities that help the Diseases of the Developing World Centre at GSK stay 
connected with the academic research community are key to bringing innovation into TB, malaria, 
and kinetoplastid drug discovery. It is for this reason that we value the close interaction with WIPO 
Re:Search to date.” –Dr. Lluis Ballell , GSK
Dr. Noemi Bahamontes, GSK
M alaria is caused by a microscopic parasite that spends part of its lifecycle inside human red blood 
cells (RBCs). The parasite metabolizes hemoglobin to 
obtain the necessary chemical ingredients to grow and 
reproduce but also produces toxic heme byproducts 
that dramatically reduce the deformability of host 
RBCs. In response, the malaria parasite sequesters toxic 
heme through its biocrystallization into inert hemozoin. 
Since the inherent deformability of RBCs is essential 
to their function, this biophysical property of RBCs 
has a complex relationship with the pathology of the 
disease. On one hand, reduced deformability is thought 
to assist the removal of the parasite by inducing 
splenic clearance. On the other hand, reduced RBC 
deformability is known to cause microvascular occlusion 
and impairment of blood flow, symptoms associated 
with severe malaria.
To better understand the relationship between 
decreased RBC deformability and malaria pathogenesis, 
Dr. Hongshen Ma from the University of British Columbia 
(UBC) has developed a simple and high-throughput 
assay for measuring RBC deformability, known as 
“cell-phoresis”. This method transports individual RBCs 
through a microstructured material in which the speed 
of transport depends on cell deformability. The final 
position of the cells can then be used as a simple, 
image-based readout for deformability, similar to DNA 
bands in gel electrophoresis. Using this approach, 
Dr. Ma’s team has made the surprising discovery that 
reduced deformability of infected red blood cells is a 
universal feature of all clinical antimalarials. This finding 
suggests that reduced infected RBC (iRBC) deformability 
is perhaps a necessary characteristic of all antimalarials 
and could potentially be used as a physical biomarker 
to screen for new drugs and adjunctive agents. This 
approach is particularly interesting because it provides 
an alternative approach to screen for compounds 
capable of inducing host-mediated clearance as part of 
their mechanism of action.
In an attempt to accelerate antimalarial development, 
GlaxoSmithKline (GSK) developed the Tres 
Cantos Antimalarial Set (TCAMS) – a set of 13,500 
compounds with activities against the blood stage 
form of P. falciparum. Through WIPO Re:Search, GSK 
has provided Dr. Ma with 15 compounds from the 
TCAMS that displayed ideal IC
50s
, had diverse effects 
on the parasite, and resulted in varying clearance 
times of iRBCs in vivo. Dr. Ma will assess the effect 
these compounds have on iRBC deformability and 
determine whether iRBC stiffness correlates with 
efficient in vivo clearance. If the results are promising, 
GSK and Dr. Ma plan to assess a larger collection of 
TCAMS compounds with a final goal of establishing 
this technology as a standard assay that will be used 
for selection of new antimalarial compounds.
University of British Columbia
GlaxoSmithKline
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“This collaboration has been crucial to extending the application of our tangential flow filtration 
technology originally intended for concentrating bacteria and viruses to new applications such as 
detection of parasites, in this case helminths.” – Dr. P. Ravi Selvaganapathy, McMaster University
Dr. Ricardo Izurieta, USF
S oil-transmitted helminths infect approximately 1.5 billion people worldwide, resulting in 
diarrhea, abdominal pain, general malaise, and 
weakness. The helminths responsible for these 
infections—roundworms (Ascaris), whipworms 
(Trichuris), and hookworms (Necator and 
Ancylostoma)—are transmitted through contact 
with or consumption of soil contaminated with 
parasite egg-ridden feces. Improving sanitation 
in endemic regions can dramatically reduce the 
incidence of these infections. 
Dr. Ricardo Izurieta at the University of South Florida 
(USF) has developed a solar-chemical toilet that 
sanitizes waste products, however to determine the 
efficacy of the treatment, he needs to assess the 
viability of parasite eggs post treatment. The process 
of isolating eggs from sewage or environmental 
samples to assess their viability requires the filtration 
of large quantities of samples. Due to the nature 
of these samples, the filters are easily and routinely 
clogged by solid debris. An alternative device 
that could swiftly and cost-effectively isolate and 
concentrate helminth eggs from sewage samples 
would greatly aid Dr. Izurieta’s assessment of the 
solar-chemical toilet.
To assist Dr. Izurieta with his work, BVGH 
connected him to Dr. P. Ravi Selvaganapathy, a 
biomicrofluidics expert at McMaster University in 
Canada. After several discussions with Dr. Izurieta, 
Dr. Selvaganapathy and his group have developed 
a tangential flow filtration device that uses minimal 
electricity to separate particles according to their 
size. The device can retain particulates as minute 
as two microns as well as worms as large as 400 
microns, and it is particularly useful in concentrating 
Ascaris eggs from a variety of samples.
Dr. Selvaganapathy has finished developing the 
device and has confirmed its ability to filter and 
concentrate beads the size of Ascaris eggs. Dr. 
Izurieta will now compare the device’s ability to 
isolate eggs from environmental and fecal samples 
to that of the WHO-standard technique (Kato 
Katz). If successful, this device could become the 
routine method to use when testing clinical and 
environmental samples for the presence of parasite 
eggs, thus helping to detect the parasites at their 
source and stemming their transmission. 
McMaster University
University of South Florida
Dr. P. Ravi Selvaganapathy, McMaster University
25
 “WIPO Re:Search facilitated connections with appropriate researchers and clinicians who 
have been essential in testing the emerging PATH NINA technology in low-resource settings 
and in receiving end-user feedback toward a more useful solution.” - Dr. Robert Burton, PATH
Dr. Dylan Pillai, University of Calgary
NINA Heater: Bringing Malaria 
Testing to the Field 
O ne of the main barriers to eliminating malaria is accurate and timely diagnosis of the 
disease. There are methods available to screen for 
Plasmodium falciparum infection, however many are 
not affordable, are unable to detect asymptomatic 
cases, or have long turnaround times. These 
challenges often result in asymptomatic people 
not being diagnosed and treated, resulting in 
continued malaria transmission. Newer methods, 
such as loop-mediated isothermal amplification 
(LAMP), have been created with these challenges 
in mind. However, these are still dependent upon 
consistent electricity—something that is commonly 
unavailable in many malaria-endemic regions. 
In order to address this issue, a team of researchers 
and engineers at PATH led by Dr. Robert Burton 
and Paul LaBarre developed a technology known 
as a non-instrumented nucleic acid amplification 
(NINA) heater. The NINA heater uses an exothermic 
chemical reaction to generate the heat necessary for 
DNA amplification such that no external electricity 
source is needed. A malaria LAMP assay combined 
with the NINA heater is a tool suitable for field use. 
PATH
University of Calgary
PATH and the University of         
Calgary
BVGH connected the scientists at PATH with Dr. 
Dylan Pillai, an infectious disease doctor and 
researcher at the University of Calgary in Canada, 
who works on implementing effective malaria 
diagnostics that can be used in low-resource 
settings. 
Dr. Pillai tested a pan-Plasmodium/Plasmodium 
falciparum-specific LAMP assay with the NINA heater, 
first in his laboratory at the University of Calgary 
and then in the field in Ethiopia. The NINA-LAMP 
combination was more sensitive than microscopic 
diagnosis and comparable to a nested PCR test. 
The results obtained from these studies have been 
recently published, and the group plans to further 
examine the efficacy of this combination on samples 
from 800 asymptomatic malaria patients. The 
researchers plan to publish another paper with the 
results of these studies in the near future. 
Dr. Robert Burton, PATH
PATH and the Centre Pasteur du 
Cameroun
Dr. Lawrence Ayong, a researcher at the Centre 
Pasteur du Cameroun (CPC), developed a reverse 
transcription-LAMP-based assay (RT-LAMP) to 
detect gametocytes—the transmissible form of the 
Plasmodium parasite. Developing an assay to detect 
the gametocytes will help to determine the risk of 
transmission from humans back to mosquitoes – 
an important factor as the world moves towards 
malaria elimination. BVGH connected Dr. Ayong 
with the PATH scientists, who agreed to share their 
NINA heater. Dr. Ayong’s tests of his RT-LAMP in the 
NINA heater yielded encouraging results, which he, 
along with the PATH team, plan to publish shortly. 
Dr. Lawrence Ayong, CPC
“Thanks to the WIPO Re:Search initiative, synergies are created between scientists from endemic 
countries and organizations with key technologies and products to allow for a variety of promising 
research projects that would have otherwise been largely inaccessible. Our collaboration with PATH 
is a clear example of how WIPO Re:Search is bridging the gap for NTDs and accelerating the 
development of more cost-effective and field-adaptable tools.” - Dr. Lawrence Ayong, CPC
PATH
Centre Pasteur du Cameroun
The NINA Heater is contained in a reusable-housing platform and is designed to heat micro PCR tubes using a commercial 
thermos. The low-cost, electricity-free, reusable NINA platform heater enables pathogen detection in low resource settings 
where there is no access to electricity and/or instrumentation. (Reference: Sema et al. Malaria Journal (2015) 14:44)
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“This collaboration with Ben Pinsky at Stanford has provided a unique opportunity to train a 
graduate student while advancing our malaria research program.  The experience Chika gained 
at Stanford will have a lasting impact on her scientific career. In addition, our partnership has 
achieved important milestones.  We are currently planning to implement and evaluate the 
multiplex assay in febrile patients in Lagos.” - Dr. Wellington Oyibo, University of Lagos
Dr. Ben Pinsky, Stanford and Dr. Wellington Oyibo, University of Lagos
Developing Diagnostics: Bringing 
Malaria Testing to the Field 
D engue fever and malaria, the two most prevalent mosquito-borne diseases worldwide, 
are not only difficult to treat, but also to diagnose. 
This is because their symptoms are non-specific 
and because the diseases are often co-endemic. 
In order to ensure more accurate diagnoses of 
febrile illnesses like dengue fever and malaria 
in developing regions, Drs. Jesse Waggoner 
and Benjamin Pinsky from Stanford University 
developed a highly sensitive real-time RT-PCR-based 
molecular diagnostic platform to simultaneously 
detect and distinguish nucleic acids from dengue 
virus and Plasmodium parasites. This platform 
can also be adapted to screen for other causes of 
undifferentiated systemic febrile illnesses, including 
leptospirosis, chikungunya, yellow fever, Rift Valley 
fever, and Zika fever. Drs. Waggoner and Pinsky are 
currently collaborating with two different partners 
to customize this platform to the diseases most 
common to Nigeria and Cameroon. 
University of Lagos 
Dr. Wellington Oyibo from the University of Lagos 
in Nigeria has collected samples from patients with 
febrile illnesses in Lagos state and was interested in 
determining the causes, besides malaria, of those 
illnesses. To address his interest, BVGH connected 
Dr. Oyibo with Drs. Waggoner and Pinsky. Following 
discussions, Drs. Waggoner and Pinsky secured 
a grant from the Stanford University Office of 
International Affairs, which allowed Dr. Oyibo’s 
graduate student, Chika Okangba, to visit Stanford 
for two months. During her stay, Chika learned how 
to collect and process patient samples, how to 
perform the Stanford multiplexed RT-PCR assay for 
dengue, malaria, and leptospirosis, and how to 
Stanford University
University of Lagos
Dengue A12-11 project funded by Institut Pasteur 
International Network). These samples were 
screened for dengue fever, chikungunya, malaria, 
and leptospirosis. Initial tests using this multiplexed 
RT-PCR assay identified a small number of dengue 
and chikungunya cases and a large proportion of 
malaria cases that were missed by conventional 
testing. Dr. Pinsky’s lab is currently screening the 
samples for an expanded set of arboviral diseases. 
Dr. Demanou has high expectations for this 
multiplex RT-PCR as the Cameroonian Government 
recently appointed his lab as the National Reference 
Laboratory for Chikungunya and Dengue. Therefore, 
Dr. Demanou hopes that he or a member of his 
team will obtain a grant from Stanford University to 
learn how to perform the Stanford multiplexed RT-
PCR assay so as to implement it at CPC.
analyze the results. Chika, with the help of Dr. 
Alisha Mohamed-Hadley, a member of the Pinsky 
laboratory, used the multiplex assay to screen 
Dr. Oyibo’s sample collection. While few cases of 
dengue or leptospirosis were identified, Chika 
confirmed the diagnosis of malaria in a significant 
number of patients that tested negative by 
microscopy.  Interestingly, the study showed that 
malaria detection using the Stanford molecular 
diagnostic on plasma and serum was more sensitive 
than, and equally specific to, microscopy in patients 
with P. falciparum malaria.  A manuscript describing 
these findings has been accepted for publication in 
the Journal of Clinical Microbiology.
Given that the samples were from patients living in 
rural areas, Dr. Pinsky and Dr. Oyibo are planning to 
collect additional samples from urban populations 
where they believe the prevalence of dengue fever 
will likely be higher.  Based on these results, the 
scientists plan to design a multiplexed RT-PCR assay 
specific to the non-malaria febrile illnesses of urban 
Nigeria.
Centre Pasteur du Cameroun 
Drs. Waggoner and Pinsky are also working with 
Dr. Maurice Demanou, a virologist who is the 
Head of Arbovirus and Hemorrhagic Fever Virus 
Laboratory and Head of WHO National Reference 
Laboratory for yellow fever and measles at the 
Centre Pasteur du Cameroun (CPC). Dr. Demanou 
believes dengue fever is underestimated in 
Cameroon and is interested in determining the 
causes and prevalence of non-malarial fevers in 
the country. Accordingly, Dr. Demanou provided 
the Pinsky laboratory with blinded clinical samples 
from Cameroonian febrile patients (collected 
and analyzed in CPC in the framework of ACIP 
“Cameroon is considered to be endemic for several arboviruses and also has high malaria 
transmission. Unfortunately, the difficulty of clinical discrimination between these infectious agents 
and the lack of adequate local laboratories constitute a real threat to the prevention and diagnosis of 
these diseases. We therefore thank WIPO Re:Search for facilitating our collaboration with Stanford, 
which has allowed our reference lab to update our diagnostic platform and to develop further 
research projects on NTDs.”- Dr. Maurice Demanou , CPC
Stanford University
Centre Pasteur du Cameroun
Dr. Maurice Demanou, CPC
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“I am very excited to have been introduced to Dr. Oyibo and the collaboration is exciting for me due to 
his extensive knowledge and for providing us access to a large collection of well-characterized 
patient samples for us to test our method.” – Dr. Paul Wiseman 
Dr. Paul Wiseman, McGill University
M alaria is an acute tropical disease that first presents with fever, chills, headache, and 
vomiting. These symptoms, which can be mild 
and indistinguishable from those caused by 
other pathogens, can progress to more severe 
disease if a patient is not promptly diagnosed 
and treated with antimalarials. The World 
Health Organization currently recommends that 
microscopy or a rapid diagnostic test be used to 
diagnose malaria, however both methods have 
their shortcomings. Diagnosis via microscopy 
requires a trained technician, whereas a rapid 
diagnostic test may not detect a low-level 
infection. A malaria diagnostic able to quickly 
detect malaria parasites within a patient sample 
is essential to mitigate disease, reduce malaria 
deaths, and limit the parasites’ transmission.   
As the head of the African Network for Drugs 
and Diagnostics Innovation (ANDI) Centre of 
Excellence for Malaria Diagnosis at the University 
of Lagos in Nigeria, Dr. Wellington Oyibo focuses 
on developing more sensitive, affordable, and 
user-friendly malaria diagnostics. Based on his 
interests, BVGH connected Dr. Oyibo with Dr. Paul 
Wiseman, a researcher at McGill University who is 
developing a diagnostic that detects a byproduct 
– hemozoin – produced by the malaria parasite.
Upon entering a red blood cell, the malaria 
parasite must metabolize hemoglobin to obtain 
the necessary molecules required to reproduce. 
This metabolic process also produces a toxic 
heme byproduct, which the parasite sequesters 
into the inert heme crystals called hemozoin. 
Dr. Wiseman is developing a diagnostic that 
detects hemozoin via laser excitation. In addition 
to being able to detect very low numbers of 
infected red blood cells, the diagnostic requires 
only a drop of blood and minimal user training, 
making it highly suitable for field studies and 
remote clinics.
Following a discussion with Dr. Wiseman, Dr. 
Oyibo agreed to share his collection of blood 
samples obtained from malaria patients and 
healthy donors from Lagos state. Dr. Wiseman 
will use these samples to validate the diagnostic, 
identify its limits of detection, and determine 
the diagnostic’s sensitivity. If the results are 
encouraging, Dr. Oyibo and Dr. Wiseman plan to 
apply for a joint grant to support the diagnostic’s 
further development into a portable device 
suitable for use throughout malaria-endemic 
regions. 
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Impact on Product Development
* BVGH FundFinder- a database developed by BVGH that summarizes open and up-
coming funding opportunities relevant to neglected infectious disease research
⁰ NIH National Institutes of Health
The process of developing new products for diseases is complicated and lengthy. On average a product takes over ten years 
to move from the bench to market, at a cost of over one billion USD. This process is further complicated for neglected disease 
products where there is no financial incentive for the developer, scarce funding, and geographical and infrastructure constraints. 
These stories highlight how WIPO Re:Search is addressing these challenges and accelerating product development.
Expediting 
R&D
Building 
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Identifying 
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In addition to facilitating research and development 
collaborations, BVGH identifies training opportunities 
for scientists. BVGH presented an opportunity to 
attend a vaccinology training course, offered by the 
International Vaccine Institute (IVI) in Seoul, Korea, 
to Dr. Mathurin Tejiokem from the Centre Pasteur du 
Cameroun and Dr. Drissa Coulibaly at the University 
of Bamako, Mali. With support from BVGH, both 
researchers applied and were selected to participate 
in the program offered and funded by IVI.
Dr. Héla Kallel from the Institut Pasteur de Tunis (IPT) has 
developed an inactivated rabies vaccine. The vaccine 
should be highly thermostable to be suitable for use 
in tropical and sub-tropical regions. The US NIH⁰ has 
the resources to address vaccine thermostability. BVGH 
connected Dr. Kallel with the NIH, which will perform 
studies on stabilization and formulation of IPT’s rabies 
vaccine under the auspices of their preclinical services 
program.
60 Degrees Pharmaceuticals 
(60P), a company focused on 
developing therapeutics for 
tropical diseases, is interested in 
repurposing modipafant to treat 
Access to clinical samples can be 
a roadblock for validation and 
development of diagnostics for NTDs, 
particularly when the R&D takes place 
dengue fever. Modipafant was 
under development by Pfizer, but 
was discontinued. Pfizer disclosed 
the Investigator’s Brochure under 
confidentiality. The data helped 60P 
design its dengue fever clinical trial, 
saving both time and money. Recently, 
60P received funding to conduct Phase 
II clinical trials using modipafant for 
dengue fever patients.
in non-endemic countries. Through 
WIPO Re:Search, researchers have gained 
access to field sites and clinical samples 
for diagnostic testing (see NINA Heater 
story on page 26). These diagnostic 
collaborations have been facilitated in
Cameroon, Nigeria, and Ethiopia 
and have provided the researchers 
with crucial data that will inform 
on their diagnostic’s design and 
development.
Accelerating 
Product 
Development
‡ NCATS National Center for Advancing Translational Sciences 
† Discovering New Therapeutic Uses for Existing Molecules (NTU†). For more infor-
mation about NTU program visit: https://ncats.nih.gov/ntu
Funding 
Support
McGill University
University of Lagos
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BVGH is incredibly proud of the progress WIPO Re:Search is making toward accelerating product development 
for neglected diseases. Since its inception in 2011, researchers around the world have come together across 
multiple sectors to combine eorts to repurpose industry assets, develop new technologies, evaluate products 
in the eld, and much more. Going forward, BVGH will continue to bring Members together around innovative 
ideas while supporting alliances to achieve important product development milestones.  We are committed to 
working in partnership with Members to make signicant contributions toward advancing discoveries and 
ultimately helping patients suering from these devastating neglected infectious diseases.  
WIPO Re:Search established
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